MedTrace Logo

Virtual Reality-based Eye Movement Desensitisation and Reprocessing Therapy for Specific Phobias

NCT06906770 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-05-28

No results posted yet for this study

Summary

The goal of this clinical trial is to study the effectiveness of a virtual reality-based eye movement desensitization and reprocessing (EMDR) application in treating phobia. It will also learn about the feasibility and safety of the application for independent use.

The main questions it aims to answer are:

Does the VR EMDR application reduce distress, improve positive cognitions, and decrease avoidance of specific phobias? Can the application help diminish phobia-related bodily sensations and encourage cognitive shifts toward positive beliefs and greater confidence in confronting previously avoided situations? Can the participants independently administer the treatment with minimum assistance?

Participants will:

Visit the site and take the VR EMDR phobia treatment every day for one week. Report their phobia and simulator sickness symptoms through self-report questionnaires or semi-structured interviews.

Conditions

  • Specific Phobias

Interventions

OTHER

Eye movement desensitization and reprocessing phobia treatment in virtual reality

Short form and frequent eye movement desensitization and reprocessing (EMDR) in virtual reality for specific phobia treatment.

Sponsors & Collaborators

  • St Andrew's Healthcare

    collaborator OTHER

  • The University of Northampton

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2025-05-02
Completion
2025-05-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06906770 on ClinicalTrials.gov